Furthermore, a randomized, placebo-controlled trial of subcutaneous IFN-α injection in patients with early SSc showed that treatment with IFN-α resulted in worsening lung function and a smaller degree of improvement in skin thickening scores compared to placebo (50). Here, IFNA1 is linked to systemic sclerosis.